| Title |
NF-κB pathway inhibitors preferentially inhibit breast cancer stem-like cells
|
|---|---|
| Published in |
Breast Cancer Research and Treatment, October 2007
|
| DOI | 10.1007/s10549-007-9798-y |
| Pubmed ID | |
| Authors |
Jiangbing Zhou, Hao Zhang, Peihua Gu, Jining Bai, Joseph B. Margolick, Ying Zhang |
| Abstract |
Accumulating evidence indicates that breast cancer is caused by cancer stem cells and cure of breast cancer requires eradication of breast cancer stem cells. Previous studies with leukemia stem cells have shown that NF-kappaB pathway is important for leukemia stem cell survival. In this study, by using MCF7 sphere cells as model of breast cancer stem-like cells, we evaluated the effect of NF-kappaB pathway specific inhibitors on human breast cancer MCF7 sphere cells. Three inhibitors including parthenolide (PTL), pyrrolidinedithiocarbamate (PDTC) and its analog diethyldithiocarbamate (DETC) were found to preferentially inhibit MCF7 sphere cell proliferation. These compounds also showed preferential inhibition in term of proliferation and colony formation on MCF7 side population (SP) cells, a small fraction of MCF7 cells known to enrich in breast cancer stem-like cells. The preferential inhibition effect of these compounds was due to inhibition of the NF-kappaB activity in both MCF7 sphere and MCF7 cells, with higher inhibition effect on MCF7 sphere cells than on MCF7 cells. PDTC was further evaluated in vivo and showed significant tumor growth inhibition alone but had better tumor growth inhibition in combination with paclitaxel in the mouse xenograft model than either PDTC or paclitaxel alone. This study suggests that breast cancer stem-like cells could be selectively inhibited by targeting signaling pathways important for breast cancer stem-like cells. |
Mendeley readers
The data shown below were compiled from readership statistics for 77 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 1% |
| Mexico | 1 | 1% |
| Germany | 1 | 1% |
| Unknown | 74 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 16 | 21% |
| Researcher | 12 | 16% |
| Student > Bachelor | 11 | 14% |
| Student > Doctoral Student | 7 | 9% |
| Professor > Associate Professor | 6 | 8% |
| Other | 16 | 21% |
| Unknown | 9 | 12% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 26 | 34% |
| Medicine and Dentistry | 12 | 16% |
| Biochemistry, Genetics and Molecular Biology | 11 | 14% |
| Pharmacology, Toxicology and Pharmaceutical Science | 6 | 8% |
| Chemistry | 3 | 4% |
| Other | 7 | 9% |
| Unknown | 12 | 16% |
Attention Score in Context
This research output has an Altmetric Attention Score of 6. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 August 2021.
All research outputs
#4,749,004
of 22,992,311 outputs
Outputs from Breast Cancer Research and Treatment
#898
of 4,677 outputs
Outputs of similar age
#14,082
of 76,813 outputs
Outputs of similar age from Breast Cancer Research and Treatment
#5
of 36 outputs
Altmetric has tracked 22,992,311 research outputs across all sources so far. Compared to these this one has done well and is in the 76th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 4,677 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has gotten more attention than average, scoring higher than 74% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 76,813 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.
We're also able to compare this research output to 36 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 66% of its contemporaries.